BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37126020)

  • 21. Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations.
    Bobbili PJ; Ivanova J; Solit DB; Mettu NB; McCall SJ; Dhawan M; DerSarkissian M; Arondekar B; Chang J; Niyazov A; Lee J; Huq R; Green M; Turski M; Lam P; Muthukumar A; Guo T; Mohan M; Zhang A; Duh MS; Oh WK
    Clin Genitourin Cancer; 2024 Jun; 22(3):102080. PubMed ID: 38653037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
    Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
    EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway.
    Mahlow J; Barry M; Albertson DJ; Jo YJ; Balatico M; Seasor T; Gebrael G; Kumar SA; Sayegh N; Tripathi N; Agarwal N; Swami U; Sirohi D
    Hum Pathol; 2024 Feb; 144():28-33. PubMed ID: 38278448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study.
    Joris S; Denys H; Collignon J; Rasschaert M; T'Kint de Roodenbeke D; Duhoux FP; Canon JL; Tejpar S; Mebis J; Decoster L; Aftimos P; De Grève J
    ESMO Open; 2023 Dec; 8(6):102041. PubMed ID: 37852034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
    Carter HB; Helfand B; Mamawala M; Wu Y; Landis P; Yu H; Wiley K; Na R; Shi Z; Petkewicz J; Shah S; Fantus RJ; Novakovic K; Brendler CB; Zheng SL; Isaacs WB; Xu J
    Eur Urol; 2019 May; 75(5):743-749. PubMed ID: 30309687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Germline and somatic DNA repair gene alterations in prostate cancer.
    Dall'Era MA; McPherson JD; Gao AC; DeVere White RW; Gregg JP; Lara PN
    Cancer; 2020 Jul; 126(13):2980-2985. PubMed ID: 32315455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries.
    Abdi B; Basset N; Perrot E; Benderra MA; Khalil A; Oudard S; Blanchet P; Brureau L; Coulet F; Cussenot O; Cancel-Tassin G
    Prostate; 2022 Sep; 82(12):1196-1201. PubMed ID: 35652560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
    Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
    Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients.
    Cussenot O; Timms KM; Perrot E; Blanchet P; Brureau L; Solimeno C; Fromont G; Comperat E; Cancel-Tassin G
    Eur Urol Oncol; 2024 Jun; 7(3):597-604. PubMed ID: 38182487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of BRCA2 Mutated Prostate Cancer at Presentation.
    Han H; Park CK; Cho NH; Lee J; Jang WS; Ham WS; Choi YD; Cho KS
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomic and Clinicopathologic Characterization of
    Kaur H; Salles DC; Murali S; Hicks JL; Nguyen M; Pritchard CC; De Marzo AM; Lanchbury JS; Trock BJ; Isaacs WB; Timms KM; Antonarakis ES; Lotan TL
    Clin Cancer Res; 2020 Sep; 26(18):4869-4881. PubMed ID: 32694154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does tumorigenesis select for or against mutations of the DNA repair-associated genes BRCA2 and MRE11?: considerations from somatic mutations in microsatellite unstable (MSI) gastrointestinal cancers.
    van der Heijden MS; Brody JR; Elghalbzouri-Maghrani E; Zdzienicka MZ; Kern SE
    BMC Genet; 2006 Jan; 7():3. PubMed ID: 16417627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer.
    Dawson NA; Zibelman M; Lindsay T; Feldman RA; Saul M; Gatalica Z; Korn WM; Heath EI
    Mol Cancer Ther; 2020 Jun; 19(6):1373-1382. PubMed ID: 32220973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
    Carlson AS; Acevedo RI; Lim DM; Gulati R; Gawne A; Sokolova AO; Cheng HH; Nelson PS; Montgomery RB; Yu EY; Schweizer MT
    PLoS One; 2020; 15(9):e0239686. PubMed ID: 32997692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.
    D'Angelo E; Espinosa I; Felicioni L; Buttitta F; Prat J
    Hum Pathol; 2023 Nov; 141():15-21. PubMed ID: 37673346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound.
    Chi KN; Barnicle A; Sibilla C; Lai Z; Corcoran C; Barrett JC; Adelman CA; Qiu P; Easter A; Dearden S; Oxnard GR; Agarwal N; Azad A; de Bono J; Mateo J; Olmos D; Thiery-Vuillemin A; Harrington EA
    Clin Cancer Res; 2023 Jan; 29(1):81-91. PubMed ID: 36043882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extreme Response to High-dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer.
    Teply BA; Kachhap S; Eisenberger MA; Denmeade SR
    Eur Urol; 2017 Mar; 71(3):499. PubMed ID: 27692705
    [No Abstract]   [Full Text] [Related]  

  • 38. Homologous recombination repair gene mutations in Chinese localized and locally advanced prostate cancer patients.
    Jiang X; Hu X; Gu Y; Li Y; Jin M; Zhao H; Gao R; Huang Z; Lu J
    Pathol Res Pract; 2021 Aug; 224():153507. PubMed ID: 34102435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.
    Vokes NI; Galan Cobo A; Fernandez-Chas M; Molkentine D; Treviño S; Druker V; Qian Y; Patel S; Schmidt S; Hong L; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee JJ; Negrao MV; Gibbons DL; Vaporciyan A; Le X; Wu J; Zhang J; Rigney U; Iyer S; Dean E; Heymach JV
    Clin Cancer Res; 2023 Dec; 29(23):4958-4972. PubMed ID: 37733794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
    Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
    Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.